Vivesto (VIVE.ST) Stock Price

Vivesto Price

OMX·CLOSED
8.70SEK-0.12 (-1.37 %)
Market closed

Over the last 6 years Vivesto grew revenue by 34.4% annually, reaching 1.02 M SEK. For Vivesto, the net margin of -36,031.4% is down versus -10,166.9% a few years ago. The stock trades about 14% above its 52-week low.

Vivesto stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Vivesto over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vivesto stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vivesto's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Vivesto Stock Price History
DateVivesto Price
8/7/20268.70 SEK
8/6/20268.82 SEK
8/5/20268.96 SEK
8/4/20268.52 SEK
7/31/20268.38 SEK
7/30/20268.43 SEK
7/29/20268.64 SEK
7/28/20268.30 SEK
7/27/20268.70 SEK
7/24/20268.85 SEK
7/23/20268.40 SEK
7/22/20268.60 SEK
7/21/20268.78 SEK
7/20/20268.80 SEK
7/17/20268.90 SEK
7/15/20268.30 SEK
7/14/20268.72 SEK
7/13/20268.44 SEK
7/10/20268.45 SEK
7/9/20268.59 SEK
7/8/20268.60 SEK
7/7/20268.16 SEK
7/6/20268.49 SEK
7/3/20268.30 SEK
7/2/20268.40 SEK
7/1/20268.70 SEK
6/30/20268.50 SEK
6/29/20268.51 SEK
6/26/20268.59 SEK
6/25/20268.60 SEK
6/24/20268.88 SEK
6/23/20268.90 SEK
6/22/20268.62 SEK
6/18/20268.95 SEK
6/17/20268.80 SEK
6/16/20268.90 SEK
6/15/20269.10 SEK
6/12/20268.66 SEK
6/11/20268.70 SEK
6/10/20268.92 SEK
6/9/20269.18 SEK
6/8/20269.18 SEK
6/5/20269.12 SEK
6/4/20269.09 SEK
6/3/20268.90 SEK
6/2/20269.70 SEK
6/1/20269.70 SEK
5/29/202610.74 SEK
5/28/202611.40 SEK
5/27/202611.62 SEK
5/26/202612.36 SEK
5/25/202614.40 SEK
5/22/202617.00 SEK
5/21/202612.15 SEK
5/20/20268.40 SEK
5/19/20268.40 SEK
5/18/20268.68 SEK
5/15/20268.90 SEK
5/13/20268.40 SEK
5/12/20268.52 SEK
5/11/20268.80 SEK
5/8/20268.34 SEK
5/7/20268.00 SEK
5/6/20268.10 SEK
5/5/20268.10 SEK
5/4/20268.48 SEK
4/30/20268.40 SEK
4/29/20268.12 SEK
4/28/20268.22 SEK
4/27/20268.10 SEK
4/24/20268.00 SEK
4/23/20267.90 SEK
4/22/20267.90 SEK
4/21/20268.08 SEK
4/20/20267.98 SEK
4/17/20267.86 SEK
4/16/20268.06 SEK
4/15/20268.10 SEK
4/14/20268.18 SEK
4/13/20267.84 SEK
4/10/20267.74 SEK
4/9/20267.74 SEK
4/8/20268.22 SEK
4/7/20268.20 SEK
4/2/20267.90 SEK
4/1/20267.61 SEK
3/31/20268.05 SEK
3/30/20267.76 SEK
3/27/20268.10 SEK
3/26/20268.32 SEK
3/25/20268.10 SEK
3/24/20268.10 SEK
3/23/20268.00 SEK
3/20/20268.08 SEK
3/19/20268.00 SEK
3/18/20268.27 SEK
3/17/20268.18 SEK
3/16/20268.13 SEK
3/13/20268.35 SEK
3/12/20268.03 SEK
3/11/20268.00 SEK
3/10/20268.17 SEK
3/9/20268.00 SEK
3/6/20268.28 SEK
3/5/20268.20 SEK
3/4/20268.26 SEK
3/3/20268.12 SEK
3/2/20268.28 SEK
2/27/20268.10 SEK
2/26/20268.11 SEK
2/25/20268.97 SEK
2/24/20268.20 SEK
2/23/20268.30 SEK
2/20/20268.67 SEK
2/19/20268.33 SEK
2/18/20268.73 SEK
2/17/20268.70 SEK
2/16/20268.67 SEK
2/13/20269.42 SEK
2/12/20269.06 SEK
2/11/20269.62 SEK
2/10/20269.80 SEK
2/9/20268.50 SEK
2/6/20268.64 SEK
2/5/20268.27 SEK
2/4/20268.02 SEK
2/3/20268.43 SEK
2/2/20268.89 SEK
1/30/20269.91 SEK
1/29/20269.44 SEK
1/28/20269.60 SEK
1/27/20269.51 SEK
1/26/20269.71 SEK
1/23/20269.90 SEK
1/22/202611.00 SEK
1/21/202610.44 SEK
1/20/202610.18 SEK
1/19/202610.32 SEK
1/16/202610.60 SEK
1/15/202610.44 SEK
1/14/202610.46 SEK
1/13/202610.80 SEK
1/12/202610.80 SEK
1/9/202611.00 SEK
1/8/202610.98 SEK
1/7/202612.20 SEK
1/5/202612.30 SEK
1/2/202611.28 SEK
12/30/202511.75 SEK
12/29/202512.25 SEK
12/23/202512.12 SEK
12/22/202511.77 SEK
12/19/202511.63 SEK
12/18/202511.28 SEK
12/17/202511.65 SEK
12/16/202511.63 SEK
12/15/202511.23 SEK
12/12/202511.35 SEK
12/11/202511.40 SEK
12/10/202511.31 SEK
12/9/202511.56 SEK
12/8/202511.31 SEK
12/5/202511.42 SEK
12/4/202511.40 SEK
12/3/202512.20 SEK
12/2/202511.56 SEK
12/1/202511.94 SEK
11/28/202512.43 SEK
11/27/202512.41 SEK
11/26/202512.01 SEK
11/25/202512.66 SEK
11/24/202514.00 SEK
11/21/202512.53 SEK
11/20/202514.24 SEK
11/19/202520.63 SEK
11/18/202520.28 SEK
11/17/202520.54 SEK
11/14/202519.71 SEK
11/13/202520.11 SEK
11/12/202520.02 SEK
11/11/202520.58 SEK
11/10/202520.67 SEK
11/7/202520.24 SEK
11/6/202520.02 SEK
11/5/202520.02 SEK
11/4/202520.19 SEK
11/3/202519.80 SEK
10/31/202519.71 SEK
10/30/202519.41 SEK
10/29/202519.41 SEK
10/28/202519.98 SEK
10/27/202519.80 SEK
10/24/202519.37 SEK
10/23/202518.93 SEK
10/22/202519.19 SEK
10/21/202519.37 SEK
10/20/202519.50 SEK
10/17/202520.15 SEK
10/16/202519.76 SEK
10/15/202519.84 SEK
10/14/202520.76 SEK
10/13/202520.54 SEK
10/10/202520.11 SEK
10/9/202520.63 SEK
10/8/202520.76 SEK
10/7/202520.06 SEK
10/6/202520.80 SEK
10/3/202519.89 SEK
10/2/202519.71 SEK
10/1/202519.93 SEK
9/30/202519.84 SEK
9/29/202520.02 SEK
9/26/202520.89 SEK
9/25/202520.28 SEK
9/24/202520.54 SEK
9/23/202519.89 SEK
9/22/202519.41 SEK
9/19/202519.76 SEK
9/18/202520.11 SEK
9/17/202519.28 SEK
9/16/202519.28 SEK
9/15/202519.71 SEK
9/12/202519.37 SEK
9/11/202519.98 SEK
9/10/202520.02 SEK
9/9/202520.11 SEK
9/8/202522.80 SEK
9/5/202520.24 SEK
9/4/202520.02 SEK
9/3/202520.32 SEK
9/2/202520.06 SEK
9/1/202520.24 SEK
8/29/202520.85 SEK
8/28/202520.76 SEK
8/27/202521.37 SEK
8/26/202521.41 SEK
8/25/202520.80 SEK
8/22/202520.89 SEK
8/21/202521.32 SEK
8/20/202520.98 SEK
8/19/202520.89 SEK
8/18/202520.89 SEK
8/15/202520.58 SEK
8/14/202521.11 SEK
8/13/202521.06 SEK
8/12/202520.98 SEK
8/11/202521.24 SEK
Access this data via the Eulerpool API
Get Free API Key

Vivesto Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
482,000.00 SEK
-131.70 M SEK
-140.27 M SEK
Jan 1, 2021
26.19 M SEK
-128.84 M SEK
-132.72 M SEK
Jan 1, 2022
1.02 M SEK
-361.83 M SEK
-365.72 M SEK
Jan 1, 2023
0.00 SEK
-132.70 M SEK
-128.74 M SEK
Jan 1, 2024 (e)
0.00 SEK
-43.86 M SEK
-54.88 M SEK
Jan 1, 2025 (e)
0.00 SEK
-34.68 M SEK
-32.93 M SEK
Jan 1, 2026 (e)
0.00 SEK
-33.66 M SEK
-21.95 M SEK
Jan 1, 2027 (e)
0.00 SEK
-48.96 M SEK
-21.95 M SEK

Vivesto Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 2:54 AM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
201620172018201920202021202220232024e2025e2026e2027e
–3.001.00201.00–26.001.00–––––
––-66.6720,000.00––-96.15–––––
–233.33-1,000.00106.97–-65.38-1,000.00–––––
2.007.00-10.00215.0018.00-17.00-10.00-10.00-10.00-10.00-10.00-10.00
-140.00-105.00-150.00-30.00-131.00-128.00-361.00-132.00-43.00-34.00-33.00-48.00
–-3,500.00-15,000.00-14.93–-492.31-36,100.00–––––
-160.00-118.00-201.00-10.00-140.00-132.00-365.00-128.00-54.00-32.00-21.00-21.00
–-26.2570.34-95.021,300.00-5.71176.52-64.93-57.81-40.74-34.38–
158.91228.61253.31398.40448.37515.15566.66618.18618.18618.18618.18618.18
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Vivesto generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vivesto retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vivesto's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Vivesto has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vivesto's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Vivesto stock margins

The Vivesto margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vivesto. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vivesto.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
106.94 %
-15.07 %
-5.22 %
Jan 1, 2020
3,753.53 %
-27,324.48 %
-29,101.66 %
Jan 1, 2021
-68.46 %
-491.92 %
-506.73 %
Jan 1, 2022
-1,049.85 %
-35,648.57 %
-36,031.43 %
Jan 1, 2023
-1,049.85 %
- %
- %
Jan 1, 2024 (e)
-1,049.85 %
- %
- %
Jan 1, 2025 (e)
-1,049.85 %
- %
- %
Jan 1, 2026 (e)
-1,049.85 %
- %
- %

Vivesto Stock Revenue, EBIT, Earnings per Share

The Vivesto earnings per share therefore indicates how much revenue Vivesto has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.51 SEK
-0.08 SEK
-0.03 SEK
Jan 1, 2020
0.00 SEK
-0.29 SEK
-0.31 SEK
Jan 1, 2021
0.05 SEK
-0.25 SEK
-0.26 SEK
Jan 1, 2022
0.00 SEK
-0.64 SEK
-0.65 SEK
Jan 1, 2023
0.00 SEK
-0.21 SEK
-0.21 SEK
Jan 1, 2024 (e)
0.00 SEK
-0.07 SEK
-0.09 SEK
Jan 1, 2025 (e)
0.00 SEK
-0.06 SEK
-0.05 SEK
Jan 1, 2026 (e)
0.00 SEK
-0.05 SEK
-0.04 SEK

Vivesto business model & stock analysis

Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in the development and marketing of innovative cancer and pain medications. The company was founded in 1998 and is headquartered in Uppsala, Sweden.

Vivesto SWOT Analysis

Strengths

Oasmia Pharmaceutical AB has several strengths that contribute to its success:

  • Strong portfolio of innovative pharmaceutical products
  • Patented drug delivery technologies
  • Well-established relationships with key partners and suppliers
  • Experienced and knowledgeable leadership team
  • Strong financial position and steady revenue growth

Weaknesses

Despite its strengths, Oasmia Pharmaceutical AB also faces certain weaknesses:

  • Limited market presence compared to larger pharmaceutical companies
  • Dependence on a small number of key products
  • Relatively low brand recognition
  • Challenges in penetrating and expanding into new markets
  • Potential regulatory and compliance risks

Opportunities

Oasmia Pharmaceutical AB can explore various opportunities to drive growth and expansion:

  • Increasing demand for innovative cancer treatments
  • Expansion into emerging markets with unmet medical needs
  • Potential partnerships and collaborations for research and development
  • Exploring new drug delivery technologies and formulations
  • Acquiring or licensing new product candidates

Threats

Oasmia Pharmaceutical AB also faces several threats that could impact its business:

  • Intense competition from larger pharmaceutical companies
  • Stringent regulatory requirements and approvals
  • Market volatility and economic downturns
  • Risks associated with intellectual property rights
  • Uncertain reimbursement policies and pricing pressures

Vivesto Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Vivesto historical P/E ratio, EBIT multiple, and P/S ratio

Vivesto annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Vivesto shares outstanding

The number of shares of Vivesto was 618.18 M in 2025. This indicates how many shares Vivesto is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
398.40 M Stocks
Jan 1, 2020
448.37 M Stocks
Jan 1, 2021
515.15 M Stocks
Jan 1, 2022
566.66 M Stocks
Jan 1, 2023
618.18 M Stocks
Jan 1, 2024 (e)
618.18 M Stocks
Jan 1, 2025 (e)
618.18 M Stocks
Jan 1, 2026 (e)
618.18 M Stocks
Price targets and forecasts for Vivesto are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Vivesto stock

33/100
20
Environment
23
Social
56
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees39
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vivesto shareholder structure

% Name
0.50512%
SEB Investment Management AB
SEB Investment Management AB
0.32801%
Skandia Fonder AB
Skandia Fonder AB
0.24643%
FCG Fonder AB
FCG Fonder AB
0.06090%
Skandia Investment Management AB
Skandia Investment Management AB
0.05496%
Storebrand Kapitalforvaltning AS
Storebrand Kapitalforvaltning AS
0.01617%
Storebrand Fonder AB
Storebrand Fonder AB

Vivesto Executives and Management Board

8 members · avg. age 53 · 38 % women

EK

Mr. Erik Kinnman (65)

Chief Executive Officer

4.97 M SEK

Management

RM

Mr. Robert Maiorana (63)

Acting Chief Financial Officer

–
JV

Ms. Johanna Vostin (55)

Chief Regulatory Officer

–
TZ

Ms. Teresa Zafra (37)

Chief Scientific Officer

–

Board of Directors

PZ

Mr. Peter Zonabend (45)

Non-Executive Chairman of the Board

756,000.00 SEK
PR

Mr. Paul Ryfors (42)

Independent Director

427,000.00 SEK
HH

Ms. Hege Hellstroem (60)

Independent Director

361,000.00 SEK
RT

Dr. Roger Tell (58)

Independent Director

361,000.00 SEK

Vivesto Supply Chain

Vivesto Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
HLB
Supplier·Customer·Leisure Products·KR
-0.46
0.05
-0.02
0.73
0.56
0.48
#NameTrend
1
Kazia Therapeutics
Supplier·Customer·Biotechnology·AU
0.95
0.84
0.26
0.55
0.51
-0.50

Frequently asked questions about Vivesto

The business model of Oasmia Pharmaceutical AB focuses on developing, manufacturing, and commercializing new generation drugs within human and veterinary oncology. Oasmia Pharmaceutical AB aims to improve treatment options for cancer with its unique drug delivery platform, XR-17, which enhances the efficacy and safety of existing chemotherapeutic agents. The company collaborates with international pharmaceutical partners to make its drugs available to patients worldwide. Oasmia Pharmaceutical AB combines innovative research and development with strategic partnerships to bring novel oncology treatments to the market.

Oasmia Pharmaceutical AB is primarily active in the pharmaceutical industry.

The main competitors of Oasmia Pharmaceutical AB in the market include AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, and Novartis AG.

Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in developing and commercializing novel cancer treatments. Founded in 1998, Oasmia has made significant advancements in therapeutic areas such as ovarian cancer, breast cancer, and prostate cancer. The company's primary focus is on creating innovative anticancer drugs based on their patented technology, XR17. Oasmia leads the way in providing effective treatments with fewer side effects, aiming to improve patients' quality of life. With a strong commitment to research and development, Oasmia Pharmaceutical AB strives to make a lasting impact in oncology treatment globally.

Some significant milestones achieved by Oasmia Pharmaceutical AB include the successful development and commercialization of several innovative pharmaceutical products. The company has obtained regulatory approvals for its lead product, Apealea, in various countries for the treatment of ovarian cancer. Additionally, Oasmia Pharmaceutical AB has entered into strategic partnerships and collaborations to expand its product portfolio and global reach. These milestones highlight the company's commitment to advancing medical treatments and its dedication to improving patient outcomes. Oasmia Pharmaceutical AB continues to pursue new opportunities and aims to make further progress in the field of oncology and other therapeutic areas.

Oasmia Pharmaceutical AB is primarily present in Sweden, as it is a Swedish-based pharmaceutical company.

Oasmia Pharmaceutical AB represents values of innovation, quality, and patient-centricity in the pharmaceutical industry. With a strong corporate philosophy that prioritizes scientific expertise and new drug development, Oasmia Pharmaceutical AB is dedicated to improving patient outcomes and addressing unmet medical needs. By leveraging its unique drug delivery platform technology, Oasmia Pharmaceutical AB strives to deliver effective and safe treatment options to patients worldwide. With a focus on research and development, collaboration, and commercialization of its innovative products, Oasmia Pharmaceutical AB aims to make a lasting impact in the healthcare sector while maintaining high standards of ethics and integrity.

7 analysts currently rate the Vivesto stock: 6 recommend buying, 1 holding and 0 selling.

Vivesto Analyst Price Targets 2026

Converted at the current exchange rate, the Vivesto share trades at 0.79 EUR (8.70 SEK).

The Vivesto share (VIVE.ST) is listed on 5 stock exchanges, including: Frankfurt (OMAX.F), London (0N4A.L), London (0N4A.L).

Oasmia Pharmaceutical AB is a leading pharmaceutical company specialized in the development and commercialization of drugs for the treatment of cancer and other serious diseases. The company is headquartered in Uppsala, Sweden, and is listed on the NASDAQ Stockholm. Oasmia Pharmaceutical's business model is primarily based on the development and sale of innovative drugs for cancer treatment. The company focuses on the development of drugs based on its proprietary nanotechnology platform XR-17, which allows for increasing the efficacy of cancer drugs while reducing their negative impacts on the body. Through this platform, the company has successfully developed and launched its first product Paclical, a safe and effective drug for the treatment of breast cancer, ovarian cancer, and lung cancer. Oasmia Pharmaceutical also has a second division based on the manufacturing and commercialization of veterinary drugs primarily used for small animals. In particular, the company has developed and launched a range of products for the treatment of diseases in dogs and cats, such as bone marrow cancer. To develop and market new products, Oasmia Pharmaceutical collaborates closely with various institutions and companies, such as Uppsala University. The company also has a strong pipeline in this division, focusing on the development of drug candidates for the treatment of prostate cancer, ovarian carcinoma, and adenocarcinoma. The company is committed to regularly expanding its portfolio and increasing market share. The company has also decided on a strategic expansion into new markets. Recently, Oasmia Pharmaceutical has entered into two important partnerships to bring its products and services to the US and Asian markets. These partnerships will help establish Oasmia Pharmaceutical as a provider of innovative drugs in these regions. Overall, Oasmia Pharmaceutical AB is a company specializing in the development of drugs for the treatment of cancer and other serious diseases. The company consists of two main divisions focused on the development of human and veterinary drugs. It also has a strong pipeline of drug candidates and collaborates closely with various institutions and companies to develop and market new products and services. Through its focus on innovative technologies and partnerships, Oasmia Pharmaceutical AB is on track to solidify its position as a leading pharmaceutical company.

The revenue cannot currently be calculated for Vivesto.

The expected profit of Vivesto is -21.95 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vivesto is currently -245.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vivesto stock.

The P/S cannot be calculated for Vivesto currently.

The Eulerpool Quality Score for Vivesto is 2/10.

The ISIN of Vivesto is SE0000722365. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Vivesto is 509722. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Vivesto is VIVE.ST. The ticker symbol is used to trade Vivesto shares on the stock exchange.

Vivesto paid dividends every year for the past 0 years.

Vivesto is assigned to the 'Health' sector.

The dividends of Vivesto are distributed in SEK.

All fundamentals and in-depth analysis of Vivesto

Our stock analysis for Vivesto stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vivesto. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Vivesto Stock
Vivesto Revenue→
Vivesto Stock
Vivesto Net Income→
Vivesto Stock
Vivesto P/E→
Vivesto Stock
Vivesto P/S→
Vivesto Stock
Vivesto EBIT→
Vivesto Stock
Vivesto Dividend→
Vivesto Stock
Vivesto Directors Dealings→
Vivesto Stock
Vivesto Stocks→
Vivesto Stock
Vivesto Market capitalization→
Vivesto Stock
Vivesto Debt→
Vivesto Stock
Vivesto Liabilities→
Vivesto Stock
Vivesto Equity→
Vivesto Stock
Vivesto AAQS→
Vivesto Stock
Vivesto Employees→
Vivesto Stock
Vivesto ROE→
Vivesto Stock
Vivesto ROA→
Vivesto Stock
Vivesto ROCE→
Vivesto Stock
Vivesto News→
Vivesto Stock
Vivesto Analyst Price Targets→

Health Stocks

Viveve MedicalVivani MedicalVivoryon TherapeuticsVIVA Biotech HoldingsVivosVitura HealthVivos TherapeuticsVitrolifeVivoSim LabsVitasora HealthViyash ScientificVitalhubAll Stocks A–Z →